Thomas NE - Search Results

1

Berwick M, Buller DB, Cust A, Gallagher R, Lee TK, Meyskens F, Pandey S, Thomas NE, Veierød MB, Ward S. Berwick M, et al. Among authors: thomas ne. Cancer Treat Res. 2016;167:17-49. doi: 10.1007/978-3-319-22539-5_2. Cancer Treat Res. 2016. PMID: 26601858 Review.

2

Tandem BRAF mutations in primary invasive melanomas.

Thomas NE, Alexander A, Edmiston SN, Parrish E, Millikan RC, Berwick M, Groben P, Ollila DW, Mattingly D, Conway K. Thomas NE, et al. J Invest Dermatol. 2004 May;122(5):1245-50. doi: 10.1111/j.0022-202X.2004.22523.x. J Invest Dermatol. 2004. PMID: 15140228 Free article.

3

Could BRAF mutations in melanocytic lesions arise from DNA damage induced by ultraviolet radiation?

Thomas NE, Berwick M, Cordeiro-Stone M. Thomas NE, et al. J Invest Dermatol. 2006 Aug;126(8):1693-6. doi: 10.1038/sj.jid.5700458. J Invest Dermatol. 2006. PMID: 16845408 Free article. Review.

4

Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma.

Shields JM, Thomas NE, Cregger M, Berger AJ, Leslie M, Torrice C, Hao H, Penland S, Arbiser J, Scott G, Zhou T, Bar-Eli M, Bear JE, Der CJ, Kaufmann WK, Rimm DL, Sharpless NE. Shields JM, et al. Among authors: thomas ne. Cancer Res. 2007 Feb 15;67(4):1502-12. doi: 10.1158/0008-5472.CAN-06-3311. Cancer Res. 2007. PMID: 17308088

5

Number of nevi and early-life ambient UV exposure are associated with BRAF-mutant melanoma.

Thomas NE, Edmiston SN, Alexander A, Millikan RC, Groben PA, Hao H, Tolbert D, Berwick M, Busam K, Begg CB, Mattingly D, Ollila DW, Tse CK, Hummer A, Lee-Taylor J, Conway K. Thomas NE, et al. Cancer Epidemiol Biomarkers Prev. 2007 May;16(5):991-7. doi: 10.1158/1055-9965.EPI-06-1038. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17507627

6

Distance to diagnosing provider as a measure of access for patients with melanoma.

Stitzenberg KB, Thomas NE, Dalton K, Brier SE, Ollila DW, Berwick M, Mattingly D, Millikan RC. Stitzenberg KB, et al. Among authors: thomas ne. Arch Dermatol. 2007 Aug;143(8):991-8. doi: 10.1001/archderm.143.8.991. Arch Dermatol. 2007. PMID: 17709657 Free PMC article.

7

Epidemiologic support for melanoma heterogeneity using the Surveillance, Epidemiology, and End Results Program.

Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Lachiewicz AM, et al. Among authors: thomas ne. J Invest Dermatol. 2008 Jan;128(1):243-5. doi: 10.1038/sj.jid.5701028. Epub 2007 Aug 23. J Invest Dermatol. 2008. PMID: 17713570 Free article. Corrected and republished. No abstract available.

8

Epidemiologic support for melanoma heterogeneity using the surveillance, epidemiology, and end results program.

Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Lachiewicz AM, et al. Among authors: thomas ne. J Invest Dermatol. 2008 May;128(5):1340-2. doi: 10.1038/jid.2008.18. J Invest Dermatol. 2008. PMID: 18408748 Free article. No abstract available.

9

Survival differences between patients with scalp or neck melanoma and those with melanoma of other sites in the Surveillance, Epidemiology, and End Results (SEER) program.

Lachiewicz AM, Berwick M, Wiggins CL, Thomas NE. Lachiewicz AM, et al. Among authors: thomas ne. Arch Dermatol. 2008 Apr;144(4):515-21. doi: 10.1001/archderm.144.4.515. Arch Dermatol. 2008. PMID: 18427046

10

Evaluation of the clonal origin of multiple primary melanomas using molecular profiling.

Orlow I, Tommasi DV, Bloom B, Ostrovnaya I, Cotignola J, Mujumdar U, Busam KJ, Jungbluth AA, Scolyer RA, Thompson JF, Armstrong BK, Berwick M, Thomas NE, Begg CB. Orlow I, et al. Among authors: thomas ne. J Invest Dermatol. 2009 Aug;129(8):1972-82. doi: 10.1038/jid.2009.4. Epub 2009 Mar 12. J Invest Dermatol. 2009. PMID: 19282844 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

204 results

Search Page